Immunogenicity Experience
Senior immunogenicity and immunosafety leader with over 20 years of experience spanning academia, large pharma, and consulting.
Deep expertise in immunogenicity risk assessment, measurement, and mitigation across biologics, gene therapies, vaccines, and advanced medicinal products. Proven leader in building and scaling immunogenicity functions, driving portfolio-level strategy, and supporting IND-enabling and clinical development programs globally.
- Immunosafety and in vitro safety assessment
- Biologics, mAbs, bispecifics, peptides, gene therapy, vaccines
- IND and first-in-human (FIH) risk assessment
- In vitro, in vivo, and QSP immunogenicity tools
Past Experience
My career has spanned multiple leadership roles in pharmaceutical development across large pharma and academia:
- Immunogenicity Expert Scientist / Investigative Safety Lead at Roche
- Associate Research Fellow at Pfizer
- Lecturer in Virology at University of Nottingham
Education
- PhD, Immunology - University of Oxford
Selected Publications
Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products.
Cellular Immunology, 2015
Nonclinical immunogenicity risk assessment of therapeutic proteins.
Bioanalysis, 2019
A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins.
CPT: Pharmacometrics & Systems Pharmacology, 2014
How I Work
I provide strategic and project-level guidance for biologics and advanced medicinal product development with a focus on immunogenicity risk assessment, measurement, and mitigation.
I advise companies on building fit-for-purpose immunogenicity strategies across discovery, preclinical, and clinical development, and have unique expertise developing immunogenicity Quantitative Systems Pharmacology (QSP) models.